ArticleThe Laryngoscope2026
Prognostic Value of Impaired Vocal Cord Mobility in T2N0 Glottic Cancer Treated With IMRT.
Article in The Laryngoscope, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impaired vocal cord mobility due to thyroarytenoid muscle involvement predicts poorer prognosis in T2 glottic cancer. Opportunity for refinement of the TNM 8Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the prognostic importance of impaired vocal cord mobility (VCM) in T2N0 glottic cancer.
methodsAll patients with T2N0 glottic cancer treated with partial laryngeal IMRT in 2009-2021 in our institution were retrospectively reviewed. For comparison, cohorts with T1N0 and T3N0 disease were also included. Locoregional failure (LRF), disease-free survival (DFS), and overall survival (OS) were compared among T1N0, T2N0 with normal VCM (T2-Normal-VCM), T2N0 with impaired VCM (T2-Impaired-VCM), and T3N0 groups. Multivariable analysis (MVA) assessed the prognostic value of VCM within the T2N0 group.
resultsA total of 642 cases were included: 288 T1N0, 224 T2N0 (147 T2-Normal-VCM, 77 T2-Impaired-VCM), and 130 T3N0. Median follow-up was 5.0 years (IQR 3.4-6.2). Five-year LRF for T1N0, T2-Normal-VCM, T2-Impaired-VCM, and T3N0 were 4% (95% CI 2-6), 9% (5-15), 27% (17-38), and 35% (27-44), respectively. Corresponding DFS was 83% (78-88), 80% (73-87), 55% (45-68), and 50% (41-60), while OS was 85% (80-90), 86% (80-92), 71% (61-83), and 59% (50-69), respectively. In T2N0, MVA confirmed that impaired VCM was associated with higher LRF (aHR 3.72 [95% CI 1.79-7.71], p < 0.001), lower DFS (aHR 2.74 [1.68-4.45], p < 0.001), and lower OS (aHR 2.07 [1.17-3.67], p = 0.013).
conclusionsIn this contemporary cohort, LRF rates increased stepwise from T1N0 to T2-Normal-VCM, T2-Impaired-VCM, and T3N0 glottic cancer. Within T2N0 disease, impaired VCM is an adverse prognostic factor, supporting subdivision into T2a (normal VCM) and T2b (impaired VCM) in future TNM revisions. Prospective studies are warranted to assess whether treatment intensification can improve outcomes for T2-Impaired-VCM disease. LEVEL OF EVIDENCE: 3:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.